4.8 Article

An injectable peptide hydrogel with excellent self-healing ability to continuously release salvianolic acid B for myocardial infarction

Journal

BIOMATERIALS
Volume 274, Issue -, Pages -

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2021.120855

Keywords

Myocardial infarction; Elastin-mimic hydrogel; Salvianolic acid B; Transglutaminase; Polydopamine nanoparticles

Funding

  1. Excellent Youth Foundation of Jiangsu Province, China [BK20190094]
  2. National Natural Science Foundation, China [82074125, 81773662]
  3. Collaborative Innovation Project of GuSu School of Nanjing Medical University, China [GSKY20210219]
  4. Qing Lan Project of Jiangsu Province, China
  5. Project of Suzhou Science and Technology Development Plan, China [SYSD2019187, SYSD2020243]
  6. National Key RAMP
  7. D program of China [2018YFC1706905]
  8. Postgraduate Research AMP
  9. Practice Innovation Program of Jiangsu Province, China [SJCX19_0368, KYCX20_1588]
  10. Aosaikang Project of Jiangsu Pharmaceutical Society, China [A202015]

Ask authors/readers for more resources

A self-healing elastin-mimic peptide hydrogel was developed for local drug delivery in myocardial infarction treatment, with the ability to form a high mechanical strength structure in heart tissue and prolong drug retention in the ventricular wall, thereby inhibiting ventricular remodeling and promoting angiogenesis.
Drug-loaded hydrogels can improve blood supply and inhibit extracellular matrix degradation after myocardial infarction. However, due to the continual dynamic motion of cardiac tissue, the hydrogel structure cannot be reconstructed in time, causing accelerated degradation and drug burst release. Here, a novel, superior, selfhealing elastin-mimic peptide hydrogel (EMH) was fabricated for the local delivery of salvianolic acid B (SaB). The self-healing ability of EMH is enhanced by SaB-loaded polydopamine nanoparticles (SaB-PDA). In vitro, the pre-hydrogel (SaB-PDA/pre-EMH) is endowed with excellent biocompatibility and a low viscosity, making it suitable for intramyocardial injection. Once injected into the myocardial infarction (MI) region, SaBPDA/pre-EMH can form SaB-PDA/EMH with great mechanical strength under the action of upregulated transglutaminase (TGase) in heart tissue post-MI. The superior self-healing ability of SaB-PDA/EMH allows for an increase in retention time in the beating ventricular wall. Therefore, with long-term release of SaB, SaB-PDA/ EMH can inhibit ventricular remodeling and promote angiogenesis for MI treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available